Insmed (NASDAQ:INSM) Price Target Raised to $112.00 at The Goldman Sachs Group
Insmed (NASDAQ:INSM – Get Free Report) had its price target lifted by The Goldman Sachs Group from $100.00 to $112.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 15.61% from […]
Insmed (NASDAQ:INSM – Get Free Report) had its price target lifted by The Goldman Sachs Group from $100.00 to $112.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 15.61% from […]
